sub:assertion {
  d:DB05087 v:identifier "DB05087" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05087" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05087> ;
    dv:drugbank-id "DB05087" ;
    dv:x-bindingdb <http://bio2rdf.org/bindingdb:50055913> ;
    dv:x-cas <http://bio2rdf.org/cas:38398-32-2> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:34857> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:38022> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:14924418> ;
    dct:description "Ganaxolone is the 3β-methylated synthetic analog of allopregnanolone; it belongs to a class of compounds referred to as neurosteroids. Ganaxolone is an allosteric modulator of GABAA receptors acting through binding sites which are distinct from the benzodiazepine binding site. It has activity in a broad range of animal models of epilepsy. Ganaxolone has been shown to be well tolerated in adults and children. In early phase II studies, Ganaxolone has been shown to have activity in adult patients with partial-onset seizures and epileptic children with history of infantile spasms. It is currently undergoing further development in infants with newly diagnosed infantile spasms, in women with catamenial epilepsy, and in adults with refractory partial-onset seizures."@en ;
    dct:identifier "drugbank:DB05087" ;
    dct:title "Ganaxolone"@en ;
    a dv:Drug ;
    rdfs:label "Ganaxolone [drugbank:DB05087]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05087> .
}